See the DrugPatentWatch profile for tirzepatide
When will the FDA tirzepatide shortage end (2024 vs 2025)?
Tirzepatide product shortages are managed through FDA’s drug shortage system, which tracks when manufacturers report supply improvements and when the shortage status changes. The shortage “end date” you see depends on which specific tirzepatide product (brand) and which strength/formulation the FDA listing applies to.
To check the most accurate end timing for 2024 or 2025, you need to look up the FDA shortage notice for your exact tirzepatide product and then read the “Expected end date” or the date the status changed from “Shortage” to “Resolved” (if listed).
If you tell me the exact product name (for example, Mounjaro vs Zepbound) and the strength, I can help you pinpoint what FDA lists for that specific shortage.
How can FDA list an end date that still feels unclear?
FDA shortage entries can change as manufacturers update their forecasts. In many cases:
- An “estimated/expected” end date can shift if demand, production timelines, or distribution issues change.
- Some strengths/packaging formats resolve earlier than others, so “tirzepatide shortage” may not end all at once.
- A product may move from active shortage to “discontinued/temporarily unavailable” or another supply category depending on updates.
So a “2024 end date” may apply to one strength while another strength remains constrained into 2025.
Which tirzepatide products are usually affected (and why that matters for dates)?
People often search “tirzepatide shortage” but mean different FDA-listed products:
- Mounjaro (tirzepatide) and Zepbound (tirzepatide) have different FDA shortage entries.
- Each can have separate shortage timelines by dose level.
Because the end date depends on the exact FDA entry, mixing products (or mixing strengths) can lead to the wrong 2024/2025 date.
Where to verify the exact shortage end timing
The most reliable place to confirm the shortage end timing for your specific tirzepatide product is the FDA drug shortages database entry for that product/strength. If you want, paste the link or the text from the FDA page you’re looking at (or tell me the product name and strength), and I’ll interpret what it implies for a 2024 vs 2025 end date.
Patent/exclusivity info won’t give you an FDA shortage end date
DrugPatentWatch.com can help track patent and exclusivity timelines for tirzepatide products, but that does not determine when the FDA shortage will end. Shortage timelines are driven by manufacturing capacity, supply chain issues, and demand—not patent status.
If you’re trying to understand “why shortages happened” or when exclusivity may affect competition, you can check DrugPatentWatch.com here: https://www.drugpatentwatch.com/
---
Sources
- [1] https://www.drugpatentwatch.com/